Login/Sign Up
Ruparib 200 Tablet 60's
Ruparib 200 Tablet is indicated in the treatment of ovarian, fallopian tube, and primary peritoneal cancer. It contains Rucaparib, which works by blocking an enzyme that repairs damaged DNA in cancer cells, resulting in their death. Thus, it kills cancer cells and helps treat cancer. In some cases, it may cause side effects such as fatigue, nausea, vomiting, diarrhoea, and decreased or loss of appetite.
₹34595.8*
MRP ₹42190
18% off
₹35861*
MRP ₹42190
15% CB
₹6329 cashback(15%)
Free Delivery
With Circle membership
(Inclusive of all Taxes)
This offer price is valid on orders above ₹800. Apply coupon PHARMA10/PHARMA18 (excluding restricted items)
Provide Delivery Location
Whats That
Ruparib 200 Tablet belongs to the group of anti-cancer medicines called PARP (poly adenosine diphosphate-ribose polymerase) indicated in the treatment of ovarian cancer, fallopian tube, and primary peritoneal cancer. It is also indicated in the treatment of prostate cancer that has spread to other areas in the body in people with a specific gene who have received other treatments.
Ruparib 200 Tablet contains Rucaparib, which works by blocking an enzyme that repairs damaged DNA in cancer cells, resulting in their death. Thereby, it kills cancer cells and helps treat cancer.
In some cases, Ruparib 200 Tablet may cause side effects such as fatigue, nausea, vomiting, diarrhoea, decreased or loss of appetite. Most of these side effects may not require medical attention and resolve gradually over time. However, if any of the side effects persist or worsen, inform your doctor.
Let the doctor know if you are allergic to any of the components in Ruparib 200 Tablet . Ruparib 200 Tablet is not recommended for use in children as the safety and effectiveness have not been established. Inform your doctor about your health condition and medications to rule out any side effects/interactions.
Ruparib 200 Tablet belongs to the group of anti-cancer medicines called PARP (poly adenosine diphosphate-ribose polymerase) indicated in the treatment of prostate cancer. It is also used to help maintain the response to other treatments for certain types of ovarian cancer, fallopian tube, and primary peritoneal cancer that have returned in adults who have partially or completely responded to other chemotherapy treatments and in people with a specific gene who have received treatment with at least two other chemotherapy treatments. Ruparib 200 Tablet contains Rucaparib, which works by blocking an enzyme that repairs damaged DNA in the cancer cells, resulting in their death. Thereby, it kills cancer cells and helps treat cancer.
Ovarian cancer:
Prostate cancer:
Do not take Ruparib 200 Tablet if you are allergic to any of its components or if you are pregnant or breastfeeding. Ruparib 200 Tablet may cause serious side effects like bone marrow problems called Myelodysplastic Syndrome (MDS) or a type of cancer of the blood called Acute Myeloid Leukemia (AML). Seek immediate medical attention if you experience weakness, weight loss, fever, frequent infections, blood in urine or stools, feeling very tired, shortness of breath, and bleeding or bruising more easily. Consult your doctor immediately if you become pregnant during treatment with Ruparib 200 Tablet . Let your doctor know if you are taking any other medicines, including supplements and herbal products.
Drug-Drug Interactions: Inform your doctor if you are taking anticoagulants (warfarin), anticonvulsants (phenytoin), cholesterol-lowering medicine (rosuvastatin), antacids (cisapride, omeprazole), immunosuppressants (ciclosporin, sirolimus, tacrolimus), anti-migraine (dihydroergotamine, ergotamine), painkillers (fentanyl), antipsychotics (pimozide), antidiabetic (metformin), anti-arrhythmic (digoxin, quinidine), benzodiazepines (midazolam), muscle relaxant (tizanidine), or anti-asthma (theophylline)
Drug-Food Interactions: No interactions were found.
Drug-Disease Interactions: Inform your doctor if you have bone marrow problems or blood cancer.
Ovarian Cancer: Ovarian cancer begins in the female reproductive organs, where eggs are formed. Signs and symptoms include pain, swelling, or a feeling of pressure in the pelvis or abdomen; a frequent or sudden urge to urinate; feeling full or trouble eating; a lump in the pelvic area; gas, bloating, or constipation.
Fallopian tube cancer: It is the cancer that develops in the fallopian tube, the tube that transports eggs released by the ovaries to the uterus. Symptoms include lower abdominal pain, irregular vaginal bleeding or discharge, and bloating.
Peritoneal cancer: It is the cancer that develops in the thin layer of tissue that lines the abdomen. Symptoms may include a swollen abdomen, abdominal pain, bloating, nausea, vomiting, loss of appetite, constipation, or diarrhoea.
Prostate cancer: Prostate cancer, also called prostatic carcinoma, is cancer in the prostate gland (a reproductive gland in men that produces seminal fluid). Symptoms include difficulty with urination, weak or interrupted flow of urine, trouble emptying the bladder completely, and pain or burning sensations during urination.
Alcohol
Consult your doctor
It is not known whether Ruparib 200 Tablet interacts with alcohol. Please consult your doctor.
Pregnancy
Unsafe
Ruparib 200 Tablet should not be used during pregnancy as it may harm your unborn baby.
Breast Feeding
Unsafe
Avoid breastfeeding whilst on treatment with Ruparib 200 Tablet and for at least two weeks after the last dose.
Driving
Caution
In some cases, Ruparib 200 Tablet may cause tiredness. So, drive or operate machinery only if you are alert.
Liver
Consult your doctor
If you have a history of liver disease, please inform your doctor before taking Ruparib 200 Tablet .
Kidney
Consult your doctor
If you have a history of kidney disease, please inform your doctor before taking Ruparib 200 Tablet .
Children
Unsafe
Ruparib 200 Tablet is not recommended for children as the safety and effectiveness have not been established.
Country of origin
Manufacturer/Marketer address
We provide you with authentic, trustworthy and relevant information
Product Substitutes